

Readers are encouraged to consult the online version of this *Handbook* (www.iphandbook.org) for fuller indexing, a robust search engine, and a “Web log” presentation of key content areas with comments.

Index

A

- AAAS. *See* American Association for the Advancement of Science (AAAS)
 Science and Intellectual Property in the Public Interest (SIPPI).
- AATF. *See* African Agricultural Technology Foundation (AATF).
- Abbreviated New Drug Application (ANDA), 90
- access and benefit sharing, 1469–1493
 biodiversity access agreements (BAA), 1495
 biological materials, seeds, or new crop varieties, 1461–1467
 confidentiality agreements, 1475
 finding access and benefit-sharing information, 1475
 inventions and new technology, 316
 letter of intent, 1471
 medicines, 256
 mutually agreed terms, 1473–1475
 obtaining research permits, 1464
 preparing your research permit application, 1464–1465, 1471
 prior informed consent, 31–33, 1471–1473, 1498
 scenarios, 1470–1471
- African Agricultural Technology Foundation (AATF), 1391, 1765–1774
 operating principles and strategy, 1767–1769
 IP management, 1769–1773
 IP policy, 1769
- Aeras Global TB Vaccine Foundation (Aeras), 67–69, 1249
 Vanderbilt University, and, 101
 See also product-development partnerships (PDPs).
- agrobacterium, 1841
- AIDS.
 the developed world, in, 92
 the developing world, in, 92–93
 See also HIV.
- agreements. *See* contracts and agreements.
- agricultural biotechnology
 crops of commercial interest, 1222
 Green Revolution, 1548–1549
 intrinsic integrity of organisms, 1545–1548
- agricultural biotechnology, business partnerships, 1221–1226
- American Association for the Advancement of Science (AAAS)
 Science and Intellectual Property in the Public Interest (SIPPI), 58
- ANDA. *See* Abbreviated New Drug Application.
- anticommons, 35, 79
- Argentina, 172–173
- Arizona State University, 1661–1672
- Association of University Technology Managers (AUTM), 19–20, 25, 617–623
 Better World Project, 20
 professional networking, 617–618, 620–621
- attorney, 635–639.
 policy development, role of, 635–639, 637, 1405–1414
 strategy development, role in, 636
 See also patent counsel.
- attorney-client privilege, 1377, 1382, 1414
- attorney-client relationship, 635
- Australia
 IP management and technology transfer, institutional capacities, 549
 licensing income, universities, 210
- author, definition of, 426
- AUTM. *See* Association of University Technology Managers (AUTM)
- ### B
- bacille Calmette-Guerin (BCG) vaccine, 68
- bag-tag license, 1334–1335
- Bailment Law, 697, 699, 761, 1334.
 See also material transfer agreement (MTA).
- Bayer Healthcare A.G.
 Global Alliance for TB Drug Development, and, 101–102
 Bayer Healthcare A.G. v. Housey Pharmaceuticals, 1004

- Bayh-Dole Act (Patent and Trademark Amendment Act of 1980 [35 U.S.C. §§ 200–211]), 19, 80, 156–158, 159, 266, 748–749, 795, 880, 1730
criticisms of, 159–160
limitation on assignment of rights, 701
march-in provisions for government use. *See* march-in rights or provisions.
- benefit sharing, 33–35, 1461–1467
See also traditional knowledge (TK).
- Bern Convention, 1563
- BIO Ventures for Global Health (BVGH), 72–73
- biodiversity
Green Revolution and, 1551–1553
IP and, 1496–1499
traditional knowledge, 259
valuation of, 861–875
- biodiversity access agreements, 1495, 1499 (BAA)
benefit sharing, 1502
contribution of each party, 1500–1501
IP rights, 1501
jurisdiction, 1500
pitfalls of, 1507
responsibilities, 1501
sharing financial benefits, 1502
sharing nonfinancial benefits, 1502, 1505
- biodiversity, public-private collaboration, 1497
- Biological Innovation for an Open Society (BiOS), 135, 887
- biopiracy, 1437–1438, 1495
IP and tangible property, 1438–1439
patents, and, 1438–1443
- bioprospecting, 1495–1510, 1495
INBio, in Costa Rica, 874–876
screening, payment for, 870–871
valuation, 861–876
- BiOS. *See* Biological Innovation for an Open Society (BiOS).
- biotechnology industry, 281–282, 295–296.
See also clusters or clustering.
- biotechnology patent, 351–360, 991–1008
enforcements and provisions, 997–998
- biotechnology R&D, 299–300
- Bonn Guidelines on Mutually Agreed Terms, 1474
- Brand. *See* trademark.
- Brazil, 93, 173–175, 199–200, 1747–1752
antiretroviral access, 1568–1569
authors' rights, 1565
genetic resources, 1565–1566
government incentives for innovation, 1750
IP management, 174–175, 1563–1575
IP and agriculture, 1566
IP and health, 1568–1571
national innovation system, 1563
patenting activities, 1748
plant variety protection, 1565
R&D expenditures, 199–200
technology transfer, 1563–1575
TRIPS, 1564
UNICAMP, 1747–1750
- BRCA1 and BRCA2 breast-cancer genes, 35, 36
- Brulotte v. Thys Co.*, 1003
- BVGH. *See* BIO Ventures for Global Health.
- bundling technologies, 162.
- business incubator, 1305–1314.
economic development, and 281–292, 1306–1307
services, 1311–1312
staffing, 1311
strategic planning, 1312–1313
- C**
- CAFTA. *See* Central American Free Trade Agreement (CAFTA).
- CAMBIA, 86
patent laws, 1356
- Canada, 224, 228 288–292
- Cartagena Protocol on Biosafety, 1386–1387, 1463, 1540
- CBD. *See* Convention on Biological Diversity (CBD).
- CDC. *See* Centers for Disease Control and Prevention (CDC).
- Central American Free Trade Agreement (CAFTA), 435
- Centers for Disease Control and Prevention (CDC), 32, 71, 92, 101
- C.F.R. *See* Code of Federal Regulations (CFR).
- CGIAR. *See* Consultative Group on International Agricultural Research (CGIAR).
- C.M. Rick Tomato Genetics Resource Center (TGRC), 709
- Chile, 175, 1577–1583
Fundación Chile, 567, 1579, 1845–1850
genetic engineering of grapes, 1580–1582
IP management, 175, 567–570
proposal for national system of TTOs in, 570–573
radiata pine biotechnology program, 1582
regulatory issues, 1578
technology and IP issues, 1577–1578
- China, 175–176, 1585–1592, 1673–1682
agriculture and IP protection, 1588–1591
copyright law, 1674–1675
IP laws, 175, 1673–1674
IP management and technology transfer, institutional capacities, 176, 550
IP management at Tsinghua University, 1679–1680
IP ownership, 175–176
IP rights protection, 1585–1588
ownership of IP created with government funding, 1675–1676
patent law, 1674
technology transfer and economic development, 1680–1681
- CIMMYT. *See* International Maize and Wheat Improvement Center (CIMMYT), IP policy.

- claims. *See* patent claims.
- Clayton Act (15 U.S.C. §§12–29 and 29 U.S.C. §52), 266, 267
- clinical trials *or* clinical research
in developing countries, 162, 201
- clusters *or* clustering, 281, 295–305, 317
analysis, 320–321, 322
biotechnology clusters in Canada, 288–289
companies, large, role of, 299, 325–326
examples of, 288–289
formation and development, 283, 299,
314–316, 319, 329
life science, selected, 287
Massachusetts biotechnology cluster, 314–315
models of, 285
technology transfer, 328
types of, 323, 324, 327
university, role of, 299, 300, 304, 311, 314,
325–326, 328
- Code of Federal Regulations (C.F.R.)
37 C.F.R., 265, 266, 779
- co-development agreements, 677, 1128–1129, 1855
See also contracts and agreements.
- Cohen-Boyer. *See* Stanford University.
- collaborative research agreements, 677, 717–724,
734–738
See also contracts and agreements.
- collaborative research agreements, terms and provisions
of amendments, 723
confidentiality, 721, 730–732, 735–736
IP rights and obligations, 721–722, 737
list of materials, 724
payment, 736
publications, 720–721
statement of objectives, 718
statement of work, 719–720
termination, 723
See also contracts and agreements, terms and
provisions of.
- collective work, definition of, 426
- commons, the, 882
monopolizing, 1447–1448
- Computer Generated Contract Template System
(CoGenCo), 1029–1042
- compulsory licensing, 10–11, 149, 249–250, 256–
257, 273–277
freedom to operate and, 1324
plant variety protection and, 396
remuneration, 276–277
research, 275
- confidential information. *See* undisclosed information
and data, protection of.
- confidentiality agreements, 671, 689–695, 753,
1128–1129
collaboration, in the context of, 999
exceptions and limitations, 692–694
representation, 694–695
template, 691–692
See also contracts and agreements.
- conflict of commitment. *See* institutional policies, con-
flict of interest *and* conflict of commitment.
- conflict of interest. *See* institutional policies, conflict of
interest *and* conflict of commitment.
- consent process, 478
- Consultative Group on International Agricultural
Research (CGIAR), 1318
germplasm accessions, 414–415, 1466–1470
material transfer agreement (MTA) for germ-
plasm, 526
research tools and, 85
- contracts and agreements, 120, 675–687, 728–729
civil code jurisdictions, and, 725–728
co-development agreements, 677, 1128–1129,
1855
common law jurisdictions, and, 725, 727–728
contract law and, 726–728
distributorship agreements, 678, 1921
drafting, 726–728
invention assignment agreements, 504–506,
783–784
life span of, 651–652, 652
patent license, 1865, 1877
template agreements, use and limitations of,
639, 675–676
trademark license, 1903
variety (plant) license, 1029, 1893
See also collaborative research agreements.
See also confidentiality agreements.
See also licenses.
See also licensing.
See also material transfer agreement (MTA).
See also licensing, options to commercialize
agreement.
- contracts and agreements, management systems,
652–657
data accessibility, 653–654
information technology (IT) infrastructure *or*
data systems, 656
requirements, 652–653
security, 654
system criteria, 657
- contracts and agreements, negotiation of, 1155–1163
protecting the interests of the public sector,
1160–1162
skills needed, 1156–1158
tactics for negotiating a license agreement,
1158–1160
See also licenses, negotiation of.
- contracts and agreements, terms and provisions of
adjudication 426, 774
arbitration provisions, 681, 1130, 1417
confidentiality clause, 679, 996–997
definitions, 678
dispute resolution, 1415–1427
enforcements and provisions, 997–998
fees and royalties, 995–996

- illegal/unenforceable provisions, 682
 - indemnification, 1390
 - jurisdiction, 681
 - mediation, 1419
 - parties, 678
 - recitals, preamble, and whereas clause, 678
 - signatories, 682
 - statement of completeness, 682
 - subject law, 682
 - term and termination provisions, 681, 998, 1218
 - warranties and notices, 681, 1390
 - See also* collaborative research agreements, terms and provisions of.
 - See also* confidentiality agreements.
 - See also* licenses, terms and provisions of.
 - Convention on Biological Diversity (CBD), 34, 383, 393, 1461–1462, 1469–1470, 1539
 - biodiversity defined, 1495
 - biodiversity rights and IP audits, 524
 - copyright, 339, 391–392, 759–760, 917
 - categories of works, 343
 - copyright marking, 348
 - copyright ownership, 421
 - databases, 344, 422, 521–522
 - definition, 426
 - Digital Millennium Copyright Act of 1998, 759
 - duration, 343
 - fair use, 345, 420
 - geographic information systems, 421
 - license, 426
 - online materials, 533
 - ownership of, 347
 - photographic images, 422
 - public domain, 420
 - publications, 522
 - registration, 343, 344
 - software, 344, 522–523
 - transfer of, 427
 - university use of, 636
 - video, 522
 - copyright assignment, definition of, 426
 - copyright protection and plant protection, 378–379
 - Cooperative Research and Development Agreements (CRADAs) [35 U.S.C. s 3710a], 160, 163, 269
 - Cooperative Research and Technology Enhancement Act (CREATE Act), 269
 - corn, 1819–1827
 - Cornell University, 1014–1016
 - Court of Appeals for the Federal Circuit. *See* U.S. Court of Appeals for the Federal Circuit.
 - courts, role of, 147–152
 - CRADA. *See* Cooperative Research and Development Agreements (CRADAs).
 - CREATE Act. *See* Cooperative Research and Technology Enhancement Act (CREATE Act).
 - creative work, definition of, 426
 - Cuba, 401–402
- D**
- databases, online, 1345–1361
 - data exclusivity. *See* undisclosed information and data, protection of.
 - defensive publishing, 879–895
 - definitions. *See* contracts and agreements, terms and provisions of.
 - Diamond v. Chakrabarty*, 80, 880, 1443
 - directive on patenting of biotechnology inventions, European Union, 32–33
 - disclosure and enablement requirements, 254
 - distributorship agreement, 678.
 - DND*i*. *See* Drugs for Neglected Diseases initiative (DND*i*).
 - documentation of inventions, 750, 763–771
 - laboratory notebooks, and, 773–777
 - laboratory notebook policy, 768–771
 - laboratory notebook, storage of and archival of, 767
 - Doha Declaration on the TRIPS Agreement and Public Health, 255–258, 262, 412, 1452, 1540
 - access to medicines, 256
 - compulsory licenses, 149, 256–257, 274
 - parallel imports, 256
 - parallel trade, 1429–1434
 - waivers for the production and export and import of needed pharmaceutical products, 257
 - domain name, Internet, 363
 - Donald Danforth Plant Science Center, 1683–1696
 - Drugs for Neglected Diseases initiative (DND*i*), 65–66, 1775–1782. *See also* product-development partnerships.
 - due diligence, 1341
- E**
- EAR. *See* export administration regulations (EAR) (15 C.F.R. §§ 730–774).
 - early-stage technology, marketing of, 1165–1171
 - Eastman Kodak Co. v. Goodyear Tire & Rubber Co.*, 1003
 - eggplant, 1829–1831
 - licensing insect resistance, 1830–1831
 - EMBRAPA. *See* Empresa Brasileira de Pesquisa Agropecuária.
 - employee agreement, 347
 - Empresa Brasileira de Pesquisa Agropecuária, 174–175, 1564–1568, 1748
 - entrepreneurship, 315–316, 326
 - government encouragement of, 1285–1287
 - universities, at, 313
 - EPC. *See* European Patent Convention (EPC).
 - EPO. *See* European Patent Office (EPO).
 - equitable access license, 58

- equitable estoppel, 1409–1410
 nonassertion covenants, 739–743
- ethics of patenting, 29–36
 deontological opposition to patenting living organisms, 30
 gene-related patents and, 1446–1449
 patentability of life-forms, prior consent and patenting of biological materials, 31–33, 410–411
 traditional knowledge, appropriating *or* patenting, 31
- Ethiopia, 176
- European Patent Convention (EPC), 383
- European Patent Office (EPO), 953, 954
- European Union 1593–1604
 Directive on Patenting of Biotechnology Innovations, 32–33
 framework programs and transnational cooperation, 1594–1596
 Group of Advisers on the Ethical Implications of Biotechnology, 32
 IP rights, issues in FP6, 1596–1603
 Sixth Framework Program (FP6), 1594–1603
- exclusions for *ordre public*, 254
- exclusions for methods of treatment, 254
- experimental use exemption. *See* patent law.
- export administration regulations (EAR) (15 C.F.R. §§ 730–774), 268
- F**
- fair use, 345, 420, 759, 1367, 1773
- Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co.*, 149
- field-of-use licensing, 124–126, 1113–1119
 patent drafting, 903–909
- FIOCRUZ, 1564
- Finland, 296, 300–304
 Finnish Funding Agency of Technology and Innovation (TEKES), 301–302
- FTO. *See* freedom to operate (FTO).
- freedom to operate (FTO), 751–752, 1213, 1317–1327, 1329–1343, 1363–1384, 1847
 analysis, 1330–1331
 copyright information, 1359, 1367
 corporate identity, 1367
 due diligence and, 1341
 file-wrapper estoppel, 1375
 FTO opinion, 1382
 FTO team, 1331–1332
 germplasm issues, 1335–1336
 international treaty information, 1359
 interviewing researchers and, 1336–1337
 options and, 1317–1327
 patents and trade secrets, 1366
 patent counsel and, 1331–1332
 patent databases and, 1339
 patent ownership and status searches, 1375
 patent searching, 1345–1361, 1373
 plant breeders' rights, 1367–1368
 research tools, 1336–1337
 questions and 1337
 risk and, 1317–1327, 1379
 scientific databases and 1337–1339
 scope, 1370–1373
 strategy and, 1317–1327, 1378–1379
 trademark searches, 1359
 when to conduct, 1368–1370
- Fundación Chile, 567, 1579, 1845–1850
- G**
- genebank management, 395
- genetically modified crops
 legal liability and, 1385–1392
- geographic information systems, 419–429
 remote sensing (RS), 419
 software issues, 429
- geographical indications, 255, 343, 916–917
 Article 23, 260
 multilateral register, 260–261
 plant protection and, 378–379
- germplasm, 389–399
 genebank management, 395
- global access, 1–10, 63–78, 89–105
 equitable access license, 98–99
- Global Alliance for TB Drug Development (TB Alliance), 70–71, 82, 1249
 Bayer Healthcare AG, 101–102
 Chiron and, 99
See also product-development partnerships (PDPs)
- Golden Rice, 5, 48, 53, 73, 274, 1554
 material transfer agreement (MTA) and, 698–699
- government use. *See* march-in rights or provisions.
- grant-back clauses, 57
- grapes, 1845–1850
- Guaymi Indians, Panama, 32
- H**
- Hagahai tribe, Papua New Guinea, 32
- HapMap Project, 482
- Harvard University, Medicine in Need, 102–103
- Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984), 968–969, 1730
 abbreviated new drug approval (ANDA), 969
- HGDP. *See* Human Genome Diversity Project (HGDP).
- HIV, 63
 diagnostics for, 55, 994
See also AIDS.
- Human Genome Diversity Project (HGDP), 34
- Human Genome Project, 481
- humanitarian use licensing, 41–45, 47–59, 1160, 1072, 1684
- human technology transfer, 800

- I
- IAVI. *See* International AIDS Vaccine Initiative (IAVI).
- ICBGs. *See* International Cooperative Biodiversity Groups (ICBGs).
- ICIPE. *See* International Center for Insect Physiology and Ecology (ICIPE).
- International Center for Insect Physiology and Ecology (ICIPE), 1783–1786
- Imperial College, London, technology transfer program, 564
- INBio. *See* National Biodiversity Institute of Costa Rica (INBio).
- indemnification, 702, 1390, 1686, 1769
 biotechnology licenses, 1769
- India, 177, 201–202, 319, 1605–1620
 expenditure on R&D in government sector, 1606
 international cooperation for capacity building, 1618–1619
 IP policy, 177, 188
 IP ownership, 177, 202
 IP management and technology transfer, institutional capacities, 177, 549
 pharmaceutical industry of, 247, 249
 national biotechnology development strategy, 1611–1613
 R&D in the pharma industry, 1606–1607
 technology transfer policies, 201–202
 traditional knowledge, 1615–1616
- indigenous peoples, 1437–1459
- Indonesia, 177–178, 242–245
 IP policy, 238–244
- innovation systems, 282–283, 296
 biotechnology industry in, 16
 cluster model, 292–293, 315
 economic development, and, 659
 linear models, 284
 nonlinear models, 283–284
 role of universities, in, 568
 triple helix model, 286
- informed consent. *See* prior informed consent.
- Institut Pasteur v. Cambridge Biotech Corp.*, 994, 998
- Institute for OneWorld Health (iOWH), 66–67, 1249
 Celera Genomics and, 99
 University of California at Berkeley and, 99–100
See also product-development partnerships (PDPs).
- institutional policies, conflict of interest *and* conflict of commitment
 conflict of commitments, 527–533, 532, 541
 conflicts of interests, 311, 312, 527–533, 538, 541–543
 licensing decision review, University of California, 529
 Stanford University conflict of interest policy, 530
- institutional policies, IP, 239–240, 316, 485–494, 496–497, 519, 749
 administering, 489
 development, revision, and implementation, 489–490
 different forms of IP (patents, trademarks, copyright, etc.), 487
 Drugs for Neglected Diseases initiative (DND*i*), 1780–1782
 institutional mission, and, 486
 International Maize and Wheat Improvement Center (CIMMYT), IP policy, 490, 492, 493
 IP audits, 516–517
 patent policies, 49
 Wellcome Trust IP policy, 476
- institutional policies, employment and IP ownership, 177, 487–489, 572
 distribution of IP licensing income to employee inventors, 569, 572
 Massachusetts Institute of Technology (M.I.T.), IP policy, 490, 491
Standard Parts Co. v. Peck and University Patents Inc. v. Klingman et al., 498
 United States v. Dubilier Condenser Corp., 492
- internal rate of return (IRR), 212–214, 225, 226
- International AIDS Vaccine Initiative (IAVI), 67, 102
See also product-development partnerships.
- International Cooperative Biodiversity Groups (ICBGs), 1511–1517
- International Maize and Wheat Improvement Center (CIMMYT), IP policy, 490, 492, 493
- International Traffic in Arms Regulations (ITAR) (22 C.F.R. §§ 120–130), 268
- International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGR), 34, 1462–1463, 1540
 farmers' rights, or privilege, 394–395, 414–417
 material transfer agreement (MTA) under, 526
- International Union for the Protection of New Varieties of Plants (UPOV), 374–375, 382, 392, 394, 396, 402–407, 1019, 1064, 1462, 1563
 essentially derived varieties, 385–386
 distinct, uniform, stable, 383–384
 sui generis plant variety protection, 1496
 relationship between TRIPS and UPOV, 258
See also plant variety protection (PVP).
- inventions
 assignment of rights to, 495, 783–784
 conception of, 779
 deciding whether to protect, 755
 differentiated from idea, 779
 employees and, 495–505
 evaluation of, 754, 795–803
 invention disclosure, 780–783
 inventor's certificate, 785

- inventorship and, 780
 - inventorship, ownership, 781
 - inventorship, as distinguished from authorship, 780
 - licensing of, to existing companies, 799, 800, 801, 802, 803
 - licensing of, to spinouts, 799–802
 - managing invention disclosure forms, 784–785
 - marketing and licensing, 755
 - patenting of, 796–799
 - sample invention disclosure form, 787–791
 - university, 495–505
 - See also* invention assignment agreements.
 - invention assignment agreements, 783–784
 - example of, 504–505
 - invention disclosure, 779–791
 - inventor, role of, in technology transfer, 507–513
 - determination of inventorship, 508
 - disclosure of invention to technology transfer office, 754
 - entrepreneurship, and, 511–512
 - public disclosure of invention, and patentability, 753
 - relationship with patent counsel, 508, 630–31
 - relationship with technology transfer officer, 509
 - role in licensing, 509–511, 630–31
 - inventorship and ownership, 632, 757, 780, 781–782
 - invitation to collaboration, 685
 - IP assembly, 131–144.
 - See also* patent pools.
 - IP audits, 515–526
 - IP dispute resolution, 1415–1427
 - IP infringement
 - how to identify, 1406–1408
 - legal aspects, 1408–1413
 - prevention, 1413–1414
 - IP law
 - antitrust, relationship with, 267
 - court decisions, U.S., 147–152
 - developing countries, 155–156, 173–175
 - influences and determinants, 229–230
 - international agreements, conventions, treaties, 170–171
 - research exemption, 409
 - specific countries, of, 172–187, 188
 - IP policy, institutional. *See* institutional policies, IP.
 - IP ownership laws or regulations, national, 171–172
 - developing countries, 177–187
 - government research funding or contracts, under, 171
 - labor or employment law provisions, 171
 - specific countries, of, 172–187, 188
 - See also* Bayh-Dole Act (Patent and Trademark Amendment Act of 1980).
 - IP portfolio management, 1195–1201
 - IP strategy, 459–473, 917–919
 - company, large, 469
 - coordination and allocation of resources, 467
 - defensive publishing, 887
 - education, 467
 - general strategic management theory, 462–463
 - governmental, 468
 - internal, 465
 - international patent protection, 927–939
 - IP management, distinguished from, 463
 - large company, 469, 471
 - litigation, 463
 - patent application filing, 921–926
 - public sector, 468, 470–471
 - real options, 466
 - spinout and smaller companies, 469, 471
 - universal relevance, 460
 - value chain, 463, 1224–1225
 - IP valuation, 466, 805–811, 813–860
 - 25% rule, 833–838
 - 50% rule, 838–839
 - advanced tools, 852
 - auctions, 854, 856–858
 - biodiversity access agreements, 1507
 - bioprospecting, 861–875
 - company resources and, 808–810
 - cost approach, 806–807, 819–820
 - discounted cash-flow analysis with hurdle rates, 839
 - excess earning/residual value approach, 809
 - hybrid approaches, 807
 - income approach, 807
 - industry standards method, 820–830
 - marginal utility, 1167
 - market approach, 807
 - methods of, 806–807
 - negotiating price and, 818–819
 - published price lists, 824
 - options pricing method, 809
 - rating/ranking method, 830–833
 - risk and, 839
 - risk-reward model of, 839–849
 - royalties, use of industry standards to determine, 822
 - royalty rate, 807, 815–816
 - sources of value relating to IP rights, 817
 - structures, 103–104
 - technology factor method, 809
 - technology risk/rewards method, 810
 - Ireland, 202–203
 - Israel, 200–201
 - ITAR. *See* International Traffic in Arms Regulations (ITAR).
 - ITPGR. *See* International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGR).
- J**
- Japan, 1621–1650
 - IP management and technology transfer, institutional capacities, 549

Japanese Patent Office (JPO), 953, 954
 Jordan, 174, 187, 201, 238–242
 JPO. *See* Japanese Patent Office (JPO).
 jurisdiction. *See* contracts and agreements, terms and provisions of.

K

Kenya, 178–179, 1783–1786
 Africert, Ltd., 1784–1785
 King's College, London, technology transfer program, 564
 Korea, Republic of, 15–17, 401–402

L

laboratory notebooks. *See* documentation of inventions.
 landrace, 390
 Laos, 1511–1521
 Levi-Strauss, 1541
 library and database issues, example, 428
 licensing, 991–1007, 1009–1016
 administration of, 1395–1403, 1398–1401
 coexclusive licensing, 1216
 cross-licensing, 1214
 developing-country public sector institutions, by, 1127–1131
 exclusive, 1014–1015, 1019–1021, 1214, 1396
 field-of-use licensing, 903–920, 1113–1120
 grant-making organizations and, 479
 nonexclusive, 1014–1016, 1214, 1396
 open source and, 107–118
 options to commercialize agreement, 1069–1112, 1396
 plant variety licensing, 1017–1027
 procedures, 1215–1216
 small agricultural biotechnology companies and, 1213–1219
 software, 1396–1398
 sole licensing, 1216
 white knight provisions, 96
 licenses, 677–678
 agri-biotechnology and, 1010–1012
 components of, 992–998
 copyright license, 426
 definition of, 728
 enforcement and litigation, 1013–1014
 expiration, 1402
 hybrid license, 1064, 1054–1056
 incentives for, 998–999
 philanthropic and humanitarian use, 1013
 product liability provisions, 1129–1130
 research contracts and, 731–732
 reservation of rights and, 41–45
 sanctions for noncompliance, 1402
 template example, 1034–1042
 termination, effect of, 1026
 tools for, 1005–1007
 trade secrets, 1043–1057

See also contracts and agreements.
 licenses, negotiation of, 1133–1152, 1226
 licenses, terms and provisions of
 amendments to agreements, 1401–1402
 arbitration provisions, 1130
 assignment provision, 1149, 1218–1219
 boilerplate *or* standard clauses, 1219
 confidentiality, 1145
 definitions, 1135–1136
 diligence, 1142–1143, 1225–1226
 exclusivity/nonexclusivity, 679, 1225
 favored nation clause, 1150
 fees and royalties, 680–681, 995–996, 1012–1013, 1130, 1139–1140, 1217
 field of use, 1225
 force majeure, 1148–1149
 improvements, 1139, 1226
 infringements, 1141–1142
 liability clause, 1217
 licensor tasks, 1398
 milestones or diligence terms, 27, 55, 119–129, 313, 1217–1218
 obligations, 1397
 parties, 1134
 patent rights, 1216
 payments, 1225
 product-liability provisions, 679–680, 1129
 publication, 1226
 reservations of rights, 1137
 right-of-first-refusal clause, 1217
 schedules, 1151–1152
 sublicenses, right to grant, 1137–1138
 termination, 1147
 territory, 679, 1129
 trademark clause, 1066
 warranties, 1141
 whereas clauses, 1134–1135
 See also contracts and agreements, terms and provisions of.
 litigation, 133–134

M

Madey v. Duke University, 42, 81, 83, 409
 MAHYCO Inc., 1829–1831
 Malaysia, 179–180
 march-in rights *or* provisions, 57, 158, 163, 164, 274
 See also Bayh-Dole Act (Patent and Trademark Amendment Act of 1980).
 marketing, technologies, 1165–1171, 1173–1201, 1203–1212
 assessment of, 1194
 collecting information, 1178
 five *W*s and one *H* of, 1167–1170
 follow-up, 1193
 importance of, 1173–1174
 invention disclosure and, 785–786
 large companies, to, 1222–1223
 making contacts, 1186

- marginal utility, 1167
 - ranking prospects worksheet, 1185
 - rifle-shot marketing, 1209
 - shotgun marketing, 1209
 - systematic approach to, 1175–1176
 - unique selling proposition (USP), 1170–1171
 - utility, 1167
 - market segmentation, *or* price discrimination, 52–53, 75–76, 148–149
 - Markman v. Westview Instruments*, 149
 - Massachusetts Institute of Technology (M.I.T.)
 - technology licensing office, 309–310
 - material transfer agreement (MTA), 676–677, 752–753, 1334, 1396, 1849–1850
 - bailments, 698, 699
 - between universities, 703
 - companies and universities, 703–706
 - fair consideration, 705–706
 - research results, rights in and dissemination of, 704
 - terms and provisions, 700–703
 - universities to universities, 703
 - material transfer agreements, templates and examples
 - example MTA from University of California, Davis, 712–716
 - genetic resources MTA, 707–708
 - letter of agreement template, 710–711
 - plant material MTA from C.M. Rick Tomato Genetics Resource Center (TGRC), 709
 - mediation, 1414
 - Medical Research Council (U.K.), technology transfer program (Medical Research Council Technology), 564–565
 - Medicines for Malaria Venture (MMV), 69–70, 249, 481
 - GlaxoSmithKline and, 102
 - See also* product-development partnerships.
 - Mexico, 180–181
 - M.I.T. *See* Massachusetts Institute of Technology.
 - milestones. *See* licenses, terms and provisions of.
 - MMV. *See* Medicines for Malaria Venture (MMV).
 - molecular pharming and IP, 1809–1811
 - Moore v. The Regents of the University of California*, 33
 - Monsanto v. Stauffer*, 409–410
 - mutually agreed terms, 1473–1475
 - MTA. *See* material transfer agreement (MTA).
 - Myriad Genetics, 35, 36
- N**
- naked licensing, 342–343
 - National Biodiversity Institute of Costa Rica (INBio), 861–865, 874–876
 - National Institutes of Health (NIH), U.S., 32, 51, 153, 156, 158, 160, 163, 1395–1403, 1709–1718
 - guidelines on patenting and licensing of research tools, 25, 79
 - license strategies, 1714
 - white knight provisions, 96
 - NIH. *See* National Institutes of Health (NIH), U.S.
 - nonassertion covenants, 97, 739–743, 1214
 - nonassert agreement. *See* nonassertion covenants.
 - notebooks, laboratory. *See* documentation of inventions.
- O**
- open source, 107–116, 881–882
 - open-source licenses
 - academic licenses, 114–115
 - copyleft licenses, 113–114
 - options to commercialize agreement, 1069–1112, 1396
 - Orange Book, The*, 1340
 - ordre public*, 30–31, 254
 - organic farming, 1552–1553
 - Oxford University, technology transfer program (Isis Innovation), 560
- P**
- papaya ring spot virus (PRSV) resistance, 1837–1844
 - parallel imports or trade, 26, 249–250, 256, 1429–1434
 - Paris Convention (Paris Convention for the Protection of Industrial Property), 929, 942–943, 954, 1563
 - Patent Cooperation Treaty (PCT), 231–232, 340, 373–374, 922–924, 930–939, 941–952, 953–963
 - applications, selected countries, 233
 - country designation, 947–948
 - international preliminary examination, 949–950
 - international search report and written opinion, 948–949
 - national-phase entry, 950
 - non-PCT member countries, 944
 - options for filing under, 945–950
 - patent prosecution costs, 944–945
 - PCT application, 930–932
 - role of WIPO in, 945
 - patentability. *See* patent protections.
 - patent application
 - deposit of biological materials and, 973–980
 - diligence and, 784
 - field-of-use licensing and, 905–906
 - filing strategies, 932–933
 - filing with the European Patent Office, 955–956
 - filing with the Japan Patent Office, 955
 - filing with the U.S. Patent and Trademark Office, 955
 - general strategy, 921–926
 - international strategy, 316, 953–964
 - prior art and, 882–883
 - provisional applications, 897–901, 914, 924
 - regional applications, 930

- See also* Patent Cooperation Treaty (PCT).
- patent claims, 884–886
 dependent claims, 355
 independent claims, 355
- patent counsel, 625–633
 agreements, preparation and negotiation, and, 632
 dispute resolution, and, 632
 interference proceedings and, 632
 role in technology transfer offices, 629–632
 selecting, 626–629
See also attorney.
- patent databases, 1345–1361
- patent families, 1374
- patent file wrapper, 1340
- patent law, 135–136
 absolute novelty, 899–900
 balancing the costs and benefits of, 1451–1452
 contributory infringement, 1840
 direct infringement, 1839
 enablement, 884
 experimental-use exemption, 342
 first to file, 340, 773, 912
 first to invent, 340, 773, 898, 912
 inducement to infringe, 1840
 interference, 915–916
 litigation options and considerations, 957–964
 nonobviousness, 342, 883–884
 novelty, 341, 883–884
 one-year statutory bar (in U.S.), 883–884, 899
 ownership of patent rights, 346
 patent misuse, 1002–1004
 patent term extension, 968–970
 procedure, 915–916
 research exemption, 83–84, 751–752
 utility, 341–342
See also IP law.
- patent pending, 338
- patents, 339, 351–355, 391, 756–758, 1333
 biological or biotechnological subject matter, 283, 520
 design patent, 338, 341, 757–758, 913
 developing countries, and, 1450–1453
 infringement, direct, 348–349, 1403, 1404–1414
 infringement, indirect, 349
 petty patents, 338
 plant patents, 340, 392, 401, 758, 913, 1061
 trade secret, compared to, 346
 utility patent, 338, 371–373, 392, 913–914
- patent pools, 137–144, 733–734, 1792–1794
 biotechnology and, 140–142
 legal concerns/antitrust, 142
 pros and cons of, 139
 research tools and, 86
- patent protections
 bars to non-U.S. countries, 934
 plants and, 407–409
 subject areas, 283
- patent searching, 1345–1361
- Patent and Trademark Amendment Act of 1980.
See Bayh-Dole Act (Patent and Trademark Amendment Act of 1980).
- PATH. *See* Program for Appropriate Technology in Health (PATH).
- PBR. *See* plant breeders' rights (PBRs).
- PCT. *See* Patent Cooperation Treaty.
- PDP. *See* product-development partnership.
- pipeline agreement. *See* licensing, options to commercialize agreement.
- Plant Patents Act of 1930, 401
- Philippines, 181–182
- plant breeders' rights (PBRs). *See* plant variety protection (PVP).
- plant-derived pharmaceuticals, 1809–1817
 case study, hepatitis B vaccine, 1814–1816
- plant variety protection (PVP), 340, 381–387, 391, 392, 402, 758–759, 981–987, 1060, 1061, 1064–1065, 1018–1019
 application process, 396–398, 982–986
 breeders' rights or privilege, 384, 1023–1025
 compulsory licensing, 396, 406
 distinct, uniform, stable (DUS), 383–384
 farmers' rights or privileges, 384–385, 397
 indigenous knowledge, 393
 patents, compared with, 385–386
 Plant Variety Protection Act (PVPA), 375–377
 requirements, 383
 research exemption, 397
 sui generis system of, 254, 258, 402
 UPOV and plant variety protection, 374–375, 396
- Poland, 182–183
- policies, institutional. *See* institutional policies, IP.
- PPP. *See* public-private partnerships (PPPs).
- price discrimination. *See* market segmentation, or price discrimination.
- pricing, drugs or pharmaceuticals, 55–56, 162, 248.
 developing world and, 91–92
 PDPs, by, 75
- prior art
 public disclosure of invention as, 753
 secret prior art, 269
- prior informed consent, 31–33, 1471–1473, 1498
- product-development partnerships (PDPs), 20, 21, 49, 64–65, 73, 74, 76–78, 95, 96, 121–122, 156, 161, 242–243, 249, 250, 1247–1250, 1318, 1756, 1829–1831
 access to markets, 75
 business models of, 74
 challenges to, 77
 characteristics of, 1247
 early-stage licensing, 76
 market segmentation, 75
 parallel trade and, 249–250
 partnerships with for-profit companies, 1248

- production and capacity issues, 76
 - pricing, 75
 - transferring technology to, 53
 - product liability provisions. *See* licenses, terms and provisions of.
 - Program for Appropriate Technology in Health (PATH)
 - malaria, 1789–1796
 - management of IP, 1758–1759, 1760–1762
 - PDPs and IP, 1757–1760
 - prohibition of filing, 25
 - protection of undisclosed information, 255
 - PRSV resistance. *See* papaya ring spot virus resistance (PRSV).
 - public and private sectors, relationship between, 142, 327–328
 - public benefits provisions, 147–148.
 - public disclosure of invention, prior art, and patentability, 753
 - public domain, 268, 879–881
 - innovation and the, 880–881
 - open source and, 110–111
 - technologies, use of, 889–890
 - Public Patent Foundation (PPF), 734
 - public-private partnership (PPP). *See* product-development partnership (PDP).
 - publication bar. *See* patent law, one-year statutory bar (in U.S.).
 - PTO shoes, 1340
- R**
- regulatory system, regulatory approvals
 - drugs, for 14–15
 - FTO, and 1366–1367
 - interface with patents, 965–871
 - patents and, 965–971
 - vaccines, for 14–15
 - reach-through clauses, 57, 478, 704, 1004, 1125, 1334, 1800.
 - See also* licenses, terms and provisions.
 - research exemption. *See* IP law.
 - research contracts. *See* contracts and agreements; collaborative research agreements.
 - research tools, 79–88
 - agricultural research, for, 82
 - biomedical research, for, 81
 - compulsory licensing, 84
 - reservation-of-rights clause, 41–45
 - examples of, 44
 - risk management
 - FTO and, 1317–1327
 - royalties, 1025–1026, 1121–1126
 - alternatives to, 1125–1126
 - collective product, for, 1123
 - compared, 867–870
 - court determination of, 824–826
 - equity consideration, 851
 - minimums, 851
 - other IP revenue and, 828
 - packing, 1121–1126
 - products manufactured and sold where patents do not exist on 1123–1124
 - running royalty structures, 849–851
 - stacking, 1121–1126, 1505
 - tables of, 824–827
 - upfront payments, 851
 - use of industry standards to determine, 822
 - See also* licenses, terms and provisions of, fees and royalties.
 - Russia, 183–184
- S**
- science and law, 150
 - Sheffield University, technology transfer program (BioFusion PLC), 563
 - Sherman Act (15 U.S.C. §§ 1–7), 266–267
 - shop right, 346, 495, 499.
 - See also* institutional policies, IP ownership and employment.
 - signatories. *See* contracts and agreements, terms and provisions of.
 - Small Business Technology Transfer Program (STTR) (15 U.S.C. §§631), 270
 - SNP Consortium, 481
 - software
 - developed collaboratively, 424
 - IP protection, 423–424
 - licensing, 423
 - shrink-wrap and click-wrap licenses, 424
 - South Africa, 93, 101, 184–185, 401–402, 1651–1658
 - institutional IP management challenges, 1655–1657
 - IP laws, 184
 - IP management and technology transfer, institutional capacities, 184, 550
 - IP ownership, 184–185, 1652
 - technology transfer statistics, 208
 - traditional knowledge in, 235
 - Speck v. North Carolina Dairy Foundation*. *See* institutional policies, IP ownership and employment.
 - spillovers, technological, 281–282, 285, 299.
 - spinouts, 20, 219, 220, 222, 799–800, 1253–1279, 1289–1294
 - business incubation, 1301–1303
 - business plans and, 1257
 - Chile, in, 569–570
 - conflict of commitment, 1277–1279
 - conflict of interest, 312, 1275–1276, 1277–1279
 - developing countries and, 1293
 - economic development, 1254–1255
 - establishing and, 1255–1257
 - factors critical for success, 1299–1300
 - faculty recruitment and retention, and, 1255
 - financial incentives, 1255
 - IP assessment, 1256–1257

- Massachusetts Institute of Technology, from, 311
 public benefit, 1254
 research activity compared to commercial activity, 1291
 risk minimization, 1267
 risks to university, and, 1262–1263
 start-ups, and, 1295–1303
 technology transfer offices, and, 1271–1275
 university tax-exempt status, and, 1263–1266
- sponsored-research agreements. *See* collaborative research agreements.
- Stanford University, 1719–1728, 1797–1807
 Cohen-Boyer, 1720, 1797–1807
 IP management and Office of Technology Transfer, 1726–1727
 IP progression, 1725
 office of technology licensing, 581
- standard operating procedures, 583, 590–596
- Statute of Monopolies, 338
- start-ups, 1289–1294, 1295–1301
- statement of completeness. *See* contracts and agreements, terms and provisions of.
- Standard Parts Co. v. Peck*, 497.
See also institutional policies, IP ownership and employment.
- strawberry, 1833–1836
- Stevenson-Wydler Technology Innovation Act, (35 U.S.C. §3710(a)), 156–159, 266
- STTR. *See* Small Business Technology Transfer Program (STTR).
- subject law. *See* contracts and agreements, terms and provisions of.
- sui generis protection of plant varieties. *See* plant variety protection (PVP), sui generis systems of.
- T**
- tangible property. *See* material transfer agreement (MTA).
- Tanzania, 101, 185
- technology transfer, 198–199, 207–208, 1166
 clusters and, 315
 companies in developing countries, to, 53–54
 conflict of interests and. *See* institutional policies, conflict of interest *and* conflict of commitment.
 developing country universities, by, 169–170, 214–215, 567–573
 economic development *or* impact, 169–170, 214–215, 540, 666–667
 economic development model, 212, 225, 540, 547
 income-generating model, 212, 225, 547
 institutional culture and, 212–213, 541
 product-development partnerships, to, 53
 role and purpose of, 21, 24, 161–164, 165, 545
 service model, 212, 225, 547
 statistics and benchmarking data, 19–20, 210–228, 213, 217, 218, 220, 223, 224, 226, 227, 546
 technology transfer, models *or* approaches, 212, 225, 547
 translation awards to support, 480
- technology transfer office (TTO), 545–557, 749–752
 accounting, 554
 alternatives for smaller research organizations, 546
 budget and finance, 219, 538, 548–552, 562
 business plan for, 546–555, 570
 characteristics for success of, 538, 556–557
 confidentiality, within, 578
 data management and recordkeeping, 641–648, 647
 distribution of income, 569
 earnings or revenues, 200–201, 209, 210, 219, 222, 223, 224, 540
 evaluation of invention patentability and market potential, 577–578, 630, 638, 649–650
 expenses, 578
 invention disclosures, soliciting, receiving, docketing, reviewing of, 594
 leadership and oversight of senior administration, 541
 licensing, 577, 591–594, 638
 location within institutional structure, internal *or* external, 554, 571
 market research and marketing, 555–556, 577.
 mission, 541, 547–548, 750
 monitoring and enforcement, 578
 negotiation of agreements, 577, 638, 1272–1275
 office management *or* office administration, 554
 organization and operations, 545, 554–556, 575–579, 581–596, 637
 outside legal council, 554, 629–632, 638–639.
See also attorney; patent counsel.
 patenting and legal services, 554, 576–577, 630–632, 636
 physical infrastructure and office space, 575–576
 policy development, internal, 577, 637
 public relations, 555
 standard operating procedures, 583, 590–596
- technology transfer office (TTO), personnel, *or* staffing, 310, 542–543, 553–554, 561–562, 576, 579, 581–583
 clerical support, 554, 572
 organizational chart, Stanford University Office of Technology Licensing, 584
 position descriptions, 553–554, 571–572, 582–583, 582, 585–589
 training and professional development, 562, 578
- technology valuation. *See* IP valuation.

- term and termination provisions. *See* contracts and agreements, terms and provisions of.
- territory. *See* licenses, terms and provisions of.
- TK. *See* traditional knowledge (TK).
- trade secrets, 339, 345–346, 391, 423, 760–761, 917, 999–1000, 1043–1057
- best mode and enablement requirements, 1052–1053
 - Economic Espionage Act (EEA), 345–346
 - exemplary cases, 1053–1054
 - initial evaluation questionnaire, 1049–1051
 - history, of, 1045–1046
 - patent, compared to, 346, 1048–1052
 - plant protection and, 378
 - Uniform Trade Secret Act (UTSA), 345–346
- trademark, 339, 342–343, 361–369, 393, 523, 760, 916, 1059–1062
- agriculture, in, 1062–1064
 - benefits, risks, and obligations of, 1060–1061
 - collective mark, 342, 363
 - domain name. *See* domain name, Internet.
 - generic terms, 364–365, 1060
 - genericide, 364–365, 1061–1062
 - infringement, 367–368
 - licensing, 368, 1043–1057
 - Madrid system, 1064, 1065
 - misappropriation, 346
 - misconception, 365
 - plant protection and, 378–379
 - protection of, 1064
 - registration, 366
 - trade dress, 342, 363
 - trade name, 362–363
 - service mark, 362
 - university use of, 636
 - value of, 1061
- trademark, types of, 364
- arbitrary mark, 363–364, 1060
 - certification mark, 342, 363
 - descriptive mark, 1060
 - fanciful mark, 363, 1060
 - membership mark, 342
 - merely descriptive mark, 364
 - suggestive mark, 364, 1060
- Trade-Related Aspects of Intellectual Property Rights (TRIPS), 53, 83, 93, 247–250, 392, 1440, 1462, 1540, 1563
- agricultural biodiversity and, 1496
 - Article 27.3(b), 258–259. *See also* plant variety protection, sui generis system of.
 - capacity-building, 261–262
 - compulsory license, 274
 - Convention on Biological Diversity and, 259
 - data exclusivity, 255, 432
 - data protection, 432
 - disclosure and enablement requirements, 254
 - Doha Declaration, 255–258, 262, 412, 1452, 1540
 - exclusion for methods of treatment, 254
 - exclusion for morality and *ordre public*, 30–31, 254
 - exclusion for plant and animal varieties and essentially biological processes, 254
 - government use, *or* march in, 254
 - importing, 257
 - plant variety protection, 411–414
 - protection of undisclosed information, 255
 - public health, 255
 - sui generis protections of plant varieties, 254
 - trade secrets and, 1043
 - UPOV and, 258
- traditional knowledge (TK), 33–35, 248, 415, 871, 1463, 1523–1538, 1539–1559
- translation awards for technology development, 480
- case studies, 481
- TRIPS. *See* Trade-Related Aspects of Intellectual Property Rights (TRIPS).
- TTO. *See* technology transfer office (TTO).
- tuberculosis (TB), 67–68, 70–71
- tying arrangement, 267
- U**
- Uganda, 186
- undisclosed information and data, protection of, 255, 523
- data exclusivity and patents, 431–435
 - regulatory aspects, 437–455
 - regulatory data protection and agricultural chemical products, 445
 - regulatory data protection and patents, 437–440
 - regulatory data protection and pharmaceuticals, 444–445
 - regulatory data protection and TRIPS, 440–444
- Union Internationale pour la Protection des Obtentions Végétales. *See* International Union for the Protection of New Varieties of Plants (UPOV).
- University of California, 1729–1737
- IP licensing, 1735
 - technology transfer, 1729–1737
- University of California, Agricultural Experiment Station, 1739–1746
- inventions, 1740–1743
 - IP and technology transfer, 1743–1746
- University of California, Davis
- C.M. Rick Tomato Genetics Resource Center (TGRC), 709
 - Public Intellectual Property Resource for Agriculture (PIPRA), 73–74
 - reservation of rights for humanitarian use, 44
 - strawberry licensing program, 1833–1836
- University of Illinois at Chicago
- international cooperative biotechnology groups, 1512–1513

- University Patents Inc. v. Klingman et al.*, 498
- United Kingdom, 1697–1707
- IP and the national health service, 1698–1699, 1701
 - IP management and developing countries, 1705–1706
 - IP management and technology transfer, institutional capacities, 550–551, 559–565
 - license agreements, national health service, 1703
 - public sector IP, 1699–1700, 1703
- United States
- IP management and technology transfer, institutional capacities, 551–552
- United States Code (U.S.C.)
- 7 U.S.C. (U.S. plant variety protection law), 266
 - 15 U.S.C. (U.S. trademark law), 265
 - 17 U.S.C. (U.S. copyright law), 265
 - 19 U.S.C. (“unfair practices in import trade”), 270–271
 - 35 U.S.C. (U.S. patent law), 265, 266, 269
 - licensing income, universities, 210
 - See also* Bayh-Dole Act (Patent and Trademark Amendment Act of 1980); Cooperative Research and Development Agreements (CRADAs).
 - See also* Plant Variety Protection Act (PVPA).
 - See also* Stevenson-Wydler Act.
 - See also* Sherman Act.
 - See also* Clayton Act.
 - See also* Small Business Technology Transfer Program (STTR).
- U.S. Patent and Trademark Office (USPTO), 953, 954
- United States v. Dubilier Condenser Corp.*, 497
- UPOV. *See* International Union for the Protection of New Varieties of Plants (UPOV).
- U.S.C. *See* United States Code (U.S.C.).
- U.S. Court of Appeals for the Federal Circuit, 148–149
- USPTO. *See* U.S. Patent and Trademark Office (USPTO).
- V**
- valuation. *See* IP valuation.
- venture capital, 327–328, 1282–1284
- agricultural biotechnology and, 1284
 - how to attract, 1284
 - public venture capital, 301, 1281–1287
- Vietnam, 186–187
- biodiversity, 1511–1521
 - bioprospecting, 1511–1521
 - international cooperative biotechnology groups, 1511–1521
 - IP laws, 186
 - IP management and technology transfer, institutional capacities, 187
 - IP ownership, 186–187
- W**
- waivers, 257
- warranties and notices. *See* contracts and agreements, terms and provisions of.
- Wellcome Trust, 475–483
- Whitehead Institute Intellectual Property System (WIIPS), 649–650
- World Intellectual Property Organization (WIPO), 233–234
- World Trade Organization (WTO), 253–263
- WIIPS. *See* Whitehead Institute Intellectual Property System (WIIPS).
- WIPO. *See* World Intellectual Property Organization (WIPO).
- WTO. *See* World Trade Organization (WTO).
- Y**
- Yale University
- Zerit and, 93–95
- Z**
- Zambia, 101
- Zenith Radio Corp. vs. Hazeltine Research, Inc.*, 1003